Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(10 sites)

United States

Dana-Farber Cancer Institute, Boston, Massachusetts

University of Michigan, Ann Arbor, Michigan

Washington University School of Medicine, St Louis, Missouri

Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York

Memorial Sloan Kettering Cancer Center, New York, New York